Work

Abstract CT124: Interim results of a phase I clinical trial evaluating Fas ligand (FasL) blocking antibody M3T01 in adults with advanced treatment-refractory solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct124

Authors: Rom Leidner, Prakash Ambady, Emily M. Lin, Neda Jooya, Amber Ruiz, Cassandra Niemi, Christopher Darus, Binbin Zheng-Lin, Tara Foote, Ashley Drokin, Alexander T. Tran, Grayson DuRaine, Bernard Fox, Alan Korman, William L. Redmond, Matthew H. Taylor

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154741892

Cites:

Cited by:

Related to: